Merck KGaA, Darmstadt, Germany, announced a collaboration and licensing agreement with Domain Therapeutics, Strasbourg, France, to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
